Literature DB >> 25655761

Lipopolysaccharide challenge: immunological effects and safety in humans.

Stefan Zielen1, Jordis Trischler, Ralf Schubert.   

Abstract

Lipopolysaccharide (LPS) is a constituent of the outer membranes of Gram-negative bacteria and an important microbial trigger that stimulates innate immunity. It is ubiquitous; it can be inoculated from the environment via inhalation of dust. The resultant inflammatory responses are essential to early host defense but may also contribute to later and/or chronic organ injury. LPS challenge either intravenously or by inhalation has been widely used for the evaluation of anti-inflammatory reagents as well as to address basic scientific questions. The acute inhalation of LPS is used as a model of acute bronchitis in human volunteers. LPS inhalation is considered a well-established method that is safe and tolerable and aids in the improved characterization of anti-inflammatory drugs in proof-of-concept studies. This article reviews immunogenicity and safety data pertaining to LPS administration, with a particular focus on LPS inhalation, which may facilitate the optimization of its use in human research.

Entities:  

Keywords:  LPS challenge; LPS inhalation; local reactions; safety; side effects; systemic reactions

Mesh:

Substances:

Year:  2015        PMID: 25655761     DOI: 10.1586/1744666X.2015.1012158

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  9 in total

1.  Inflammation induced by inhaled lipopolysaccharide depends on particle size in healthy volunteers.

Authors:  Virginie Doyen; Gabrielle Pilcer; Phong Huy Duc Dinh; Francis Corazza; Alfred Bernard; Pierre Bergmann; Nicolas Lefevre; Karim Amighi; Olivier Michel
Journal:  Br J Clin Pharmacol       Date:  2016-07-28       Impact factor: 4.335

2.  T cell activation and IFNγ modulate organ dysfunction in LPS-mediated inflammation.

Authors:  Matthew D Taylor; Tiago D Fernandes; Omar Yaipen; Cassidy E Higgins; Christine A Capone; Daniel E Leisman; Ana Nedeljkovic-Kurepa; Mabel N Abraham; Mariana R Brewer; Clifford S Deutschman
Journal:  J Leukoc Biol       Date:  2022-02-09       Impact factor: 6.011

3.  Corneal Application of R9-SOCS1-KIR Peptide Alleviates Endotoxin-Induced Uveitis.

Authors:  Chulbul M Ahmed; Anil P Patel; Cristhian J Ildefonso; Howard M Johnson; Alfred S Lewin
Journal:  Transl Vis Sci Technol       Date:  2021-03-01       Impact factor: 3.283

4.  Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide.

Authors:  Etheresia Pretorius; Sthembile Mbotwe; Janette Bester; Christopher J Robinson; Douglas B Kell
Journal:  J R Soc Interface       Date:  2016-09       Impact factor: 4.118

Review 5.  Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives.

Authors:  Aernout van Haarst; Lorcan McGarvey; Sabina Paglialunga
Journal:  Clin Pharmacol Ther       Date:  2019-07-23       Impact factor: 6.875

6.  Helicobacter pylori infection is associated with diabetes among Chinese adults.

Authors:  Zhengce Wan; Lulu Song; Liu Hu; Mei Hu; Xiaomei Lei; Yuancheng Huang; Yongman Lv
Journal:  J Diabetes Investig       Date:  2019-07-04       Impact factor: 4.232

Review 7.  The Role of Airway Epithelial Cell Alarmins in Asthma.

Authors:  Christiane E Whetstone; Maral Ranjbar; Hafsa Omer; Ruth P Cusack; Gail M Gauvreau
Journal:  Cells       Date:  2022-03-24       Impact factor: 6.600

Review 8.  Dual Role of Toll-like Receptors in Human and Experimental Asthma Models.

Authors:  Amin Zakeri; Momtchilo Russo
Journal:  Front Immunol       Date:  2018-05-15       Impact factor: 7.561

9.  Systemic inflammatory response to inhaled endotoxin does not correlate with airway response.

Authors:  Amika K Sood; Allison J Burbank; Michael Lawson; Haibo Zhou; Heather B Wells; David B Peden; Michelle L Hernandez
Journal:  Respir Res       Date:  2019-11-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.